1. Home
  2. ARTL vs CYAB Comparison

ARTL vs CYAB Comparison

Compare ARTL & CYAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artelo Biosciences Inc.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$1.45

Market Cap

1.4M

Sector

Health Care

ML Signal

N/A

Logo Cyabra Inc. Common Stock

CYAB

Cyabra Inc. Common Stock

N/A

Current Price

$0.06

Market Cap

1.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARTL
CYAB
Founded
2011
2017
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.6M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
ARTL
CYAB
Price
$1.45
$0.06
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $1.00
AVG Volume (30 Days)
27.2K
★ 35.0M
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.03
Revenue Next Year
N/A
$77.74
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.08
52 Week High
$179.19
$3.98

Technical Indicators

Market Signals
Indicator
ARTL
CYAB
Relative Strength Index (RSI) 26.43 32.54
Support Level $0.52 N/A
Resistance Level $6.81 $0.35
Average True Range (ATR) 0.25 0.03
MACD 0.00 0.00
Stochastic Oscillator 0.00 5.76

Price Performance

Historical Comparison
ARTL
CYAB

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About CYAB Cyabra Inc. Common Stock

Cyabra Inc is an AI-powered SaaS company that detects and analyzes online disinformation. Its platform uses machine learning to monitor social media and news data in real time, identify fake accounts and harmful narratives, and assess content authenticity and sentiment.

Share on Social Networks: